Vanderbilt Researchers’ Potential Alzheimer’s Therapy Being Tested in Phase 1 Study

Vanderbilt Researchers’ Potential Alzheimer’s Therapy Being Tested in Phase 1 Study
Vanderbilt University researchers have developed a potential therapy for Alzheimer’s disease (AD) that has shown promising results in brain health. The investigative treatment, a molecule called VU319, is expected to fill a long-needed gap for Alzheimer’s patients by improving memory, attention, and brain functioning. The U.S. Food and Drug Administration (FDA) has cleared the drug to move into human clinical trials to determine the proper dose and safety profile. VU319 is currently being tested in healthy human volunteers. The first patient was dosed on July 29 in a first-in-human Phase 1 clinical trial at the Vanderbilt Institute for Clinical and Translational Research. If it passes the Phase 1 study in healthy people, VU319's abilty to improve cognitive function will be tested in patients with Alzheimer's disease and other brain disorders. VU319 was developed by a team of scientists at the Vanderbilt Center for Neuroscience Drug Discovery led by center director P. Jeffrey Conn and Craig W. Lindsley, co-director of the center. "This new small-molecule approach to potentially treating Alzheimer's disease represents an exciting advance from currently available therapies," Dr. Paul Newhouse,  director of the Vanderbilt Center for Cognitive Medicine and leader of the study, said in a press release. Newhouse and his team spent th
Subscribe or to access all post and page content.

One comment

  1. Linda Grishman says:

    How are these people getting into clinical trials? My doctor is useless so I have found my own sources. Albany Med Center has some promising results with a new drug. I will be going to Albany in the next few werks. I pray that it will clear the plaque and I will be back to my normal self. As you can see, I am still fully cognicent and that is a plus.

    Linda Grishman.
    Burlington, VT

Leave a Comment

Your email address will not be published. Required fields are marked *